论文部分内容阅读
本文研究61例多发性骨髓瘤(MM)患者,中位数年龄62岁(范围39—77岁),着重分析了高血清白细胞介素Ⅱ(IL-2)与MM患者保险统计生存间的关系。结果发现血清IL-2水平和血清β_2微球蛋白(SB2M)影响MM患者的生存,10例血清IL-2≥10U/ml者5年存活87％,51例IL-2<10U/ml者仅21％(P<0.05)。另外证实SB2M≥6μg/ml与MM患者生存具有相反的预后意义(P<0.01),所有血清
This study investigated 61 patients with multiple myeloma (MM) with a median age of 62 years (range, 39-77 years) and focused on the relationship between high serum interleukin-2 (IL-2) and the survival of MM patients. . The results showed that serum IL-2 levels and serum β2-microglobulin (SB2M) affect the survival of MM patients, 10 cases of serum IL-2 ≥10U/ml were 87% in 5 years, 51 cases of IL-2 <10U/ml only 21% (P<0.05). In addition, it was confirmed that SB2M ≥6μg/ml had the opposite prognostic significance in survival of MM patients (P<0.01).